Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
09:54am, Monday, 09'th May 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
11:45am, Thursday, 05'th May 2022 Zacks Investment Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
12:25pm, Wednesday, 04'th May 2022 Zacks Investment Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics to Participate in Upcoming May Investor Conferences
10:30am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Jo
Beam Therapeutics to Participate in Upcoming May Investor Conferences
06:30am, Wednesday, 04'th May 2022
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
02:09pm, Thursday, 28'th Apr 2022 Benzinga
Upgrades
According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago
ARKK: Cathie Wood's Secret Selling
03:10pm, Thursday, 31'st Mar 2022 Seeking Alpha
ARKK ETF has found a way to generate some fresh capital for purchases. Seven names have been sold but don't appear in the daily e-mail. See more on ARKK here.
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
10:30am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
11:30am, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
06:30am, Tuesday, 08'th Mar 2022
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gi
Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists
01:55pm, Tuesday, 01'st Mar 2022 Barron''s
The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
12:55pm, Monday, 28'th Feb 2022 Zacks Investment Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
Beam Therapeutics GAAP EPS of -$0.95, revenue of $51.07M (NASDAQ:BEAM)
11:51am, Monday, 28'th Feb 2022 Seeking Alpha
Beam Therapeutics press release (BEAM): Q4 GAAP EPS of -$0.95.Revenue of $51.07M.Shares -5.11% PM. Strong Cash Position of $1.2 Billion, Including Pfizer Upfront, to Support Robust Set…
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
11:30am, Monday, 28'th Feb 2022 GlobeNewswire Inc.
Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion
